Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

41 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

NCT05228470

Conditions
BCMA, BCMA-CD3 Bispecific, Bispecific, +23 more
Locations
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Guangdong Provincial People's Hospital Guangzhou, Guangdong, China
  • Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
View all 15 locations
View Trial Details
Completed

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

NCT03744676

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Local Institution - 0057 Los Angeles, California, United States
  • Local Institution - 0060 Denver, Colorado, United States
  • Local Institution - 0089 Miami, Florida, United States
  • Local Institution - 0081 Orlando, Florida, United States
View all 23 locations
View Trial Details
Completed

Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)

NCT05529524

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Centre Hospitalier de La Cote Basque; Hematologie Bayonne, France
  • Hopital Claude Huriez; Hematologie Lille, France
  • Institut Paoli Calmettes Marseille, France
  • CHU Saint Eloi; Service d'Hématologie Clinique Montpellier, France
View Trial Details
Completed

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

NCT02112526

Conditions
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Atlanta, Georgia, United States
  • Research Site New York, United States
  • Research Site Columbus, Ohio, United States
View Trial Details
Completed

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

NCT01183949

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Faber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan-Kettering Cancer Centre New York, United States
View Trial Details
Completed

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT01063907

Conditions
Blood Protein Disorders, Bronchial Diseases, Bronchiolitis, +28 more
Locations
  • Arizona Clinical Research Center, Inc. / Arizona Oncology Associates, 1825 N Kolb, Tucson, Arizona, United States
  • Pacific Shores Medical Group 1043 Elm Ave, Suite 104 Long Beach, California, United States
  • UCLA Medical Center Hematology / Oncology Division, 10945 Le Conte Ave #2333, Los Angeles, California, United States
  • Collaborative Research Group 2320 S Seacrest Blvd, Suite 202 Boynton Beach, Florida, United States
View all 26 locations
View Trial Details
Completed

Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

NCT02658968

Conditions
AIDS-Related Complex, Blood-Borne Infections, Communicable Diseases, +29 more
Locations
  • University of California, San Diego (UCSD) - Moores Cancer Center San Diego, California, United States
  • University of California, San Francisco (UCSF) - Innovation, Technology & Alliances San Francisco, California, United States
  • Sylvester Comprehensive Cancer Centre Miami, Florida, United States
  • Klinikum rechts der Isar der TU München Munich, Germany
View Trial Details
Completed

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

NCT02733042

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +20 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Pinnacle Oncology Hematology Scottsdale, Arizona, United States
  • University of Colorado Cancer Center Aurora, Colorado, United States
  • Shands Cancer Center University of Florida Gainesville, Florida, United States
View all 66 locations
View Trial Details
Completed

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

NCT01667133

Conditions
Bone Marrow Diseases, Chronic Disease, Chronic Myeloid Leukemia (CML), +16 more
Locations
  • Aichi Cancer Center Hospital Nagoya, Aichi-ken, Japan
  • Akita University Hospital Akita, Japan
  • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Hiroshima, Japan
  • Kyushu University Hospital Hukuoka-shi, Hukuoka, Japan
View Trial Details

Related conditions